Advances in Proximal Occlusion Devices for Carotid Angioplasty and Stenting

Original title: A Meta-Analysis of Proximal Oclusion Device Outcome in Carotid Artery Stenting Reference: Robert M Bersin, et al. Catheterization and Cardiovascular Intervention 80:1072-78 (2012)

Carotid Angioplasty and Stenting (CAS) is considered a valid alternative to treat high risk patients. Embolic protection devices have been proved effective and currently there are two EPDs available: proximal occlusion and distal occlusion devices. 

The goal of this meta-analysis was to determine risk predictors of adverse events in carotid stenting using proximal occlusion devices. 2397 patients were submitted to CAS with Mo.MA or Gore Flow Reversal System. End point was a composite of death, infarction and stroke at 30 days. Mean age was 70, 37% were diabetic and 31% were symptomatic.

The composite primary endpoint at 30 days was 2.25%.The incidence of stroke was 1.71%. The incidence of myocardial infarction was 0.02%. The incidence of death was 0.40%. The presence of contralateral occlusion was not found to predict intolerance, however a

Multivariate analysis showed that age and diabetic status were found to be the only significant independent risk predictors. A significant difference was observed in risk of stroke according to age, with a 1% chance in

Conclusion 

This meta-analysis of CAS using proximal EPDs presented a low rate of complications at 30 days; age and diabetics were the best risk predictors.

Editorial Comment:

This study is a meta-analysis that collected data from trials that studied only one branch, performed by experienced operators in good candidates. The resulting good outcomes (especially taking into account the number of diabetic and symptomatic patients) may be the best ever. This is an important limitation to this study. The important number of patients analyzed helps us have an idea of evolution at 30 days with these devices that, although quite different, act similarly and may have an advantage, at least in theory, over filters.

It would be interesting to see further controlled research comparing both devices to determine the best option, or which of them best adequate to every case in particular.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...